Top Back to top

Outcomes of HLA-mismatched HSCT in patients with PID following in vitro T-cell depletion with CD3+TCRαβ/CD19 depleted PBSC or in vivo T-cell depleted HSCT with post-transplant cyclophosphamide

Study number:
8427017
Short title:
TCR αβ or PTCY mismatched HSCT in PID
Study status:
Data collection
Deadline for data collection:
 
Study design:
Retrospective study with additional data collection
Primary objective:
To compare overall and event free survival between the two groups. Events defined as graft failure, disease recurrence, severe chronic GVHD and severe autoimmunity or death
Key inclusion criteria:
Diagnosis: Primary Immunodeficiency/Autoimmune/Autoinflammatory disorders
Type of HSCT: first HSCT with either CD3+TCR αβ/CD19 depletion in vitro or with post-transplant cyclophosphamide in vivo
Donors: mismatched donors, either haploidentical MMFD or ≤9/10 MMUD, BM and PBSC
Date of first date of HSCT: 1.1.2010-31.12.2018

If you wish to participate in this study and did not receive an invitation please contact: iewpebmt@lumc.nl
Country:
 
Principal investigator:
Mary Slatter & Michael Albert
Principal investigator email:
 
EBMT Study coordinator:
Sheree Hazelaar
Study coordinator email:
iewpebmt@lumc.nl

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org